How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?

This report provides a detailed summary of a panel session which took place at the HTAi 2016 annual meeting, Tokyo. The panel session was entitled "How Can HTA in Asia-Pacific Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?" and was chaired by Franz Pichler (Eli Lilly & Company).